Lenetix Announces Successful Study of Improved Non-invasive Test Procedure
MINEOLA, N.Y., Jan. 28 /PRNewswire/ -- Lenetix, Inc. today announced a significant step in the development of an improved first and second trimester non-invasive fetal chromosomal screening test to detect Down syndrome and other genetic fetal conditions. Lenetix presented preliminary study results at the 29th annual Society for Maternal-Fetal Medicine Conference in San Diego that indicate a potential breakthrough in testing quality and accuracy while preserving the safety of mother and fetus.
The maternal serum test developed by Lenetix medical director Dr. Stephen A. Brown at the
"The technique described by Dr. Brown and his team at Lenetix will create a revolution in prenatal diagnosis," said study investigator Allan Fisher, M.D., FACOG, FACMG. "This testing will ultimately decrease the number of amniocenteses, and thus reduce the number of miscarriages caused by amniocenteses. It will also help us identify patients who will need an amniocentesis or CVS where we may have missed them before. A better test that produces fewer false positives and negatives drives better patient care, and that's exciting for the future."
"Our preliminary results are extraordinarily encouraging, and complement nicely the work of other investigators whose efforts have focused heretofore in the 2nd trimester," said Lenetix president and CEO Leonard H. Kellner. "Such breakthroughs in improvements of current maternal serum screening for fetal aneuploidy, including fetal Down syndrome, will lead to better quality of screening and most certainly will result in less unnecessary, invasive diagnostic testing."
Founded in 2001, Mineola, NY-based Lenetix Medical Laboratory is a privately-owned provider of innovative technologies focused on diagnostic testing, including prenatal and reproductive cancer diagnostics, and risk assessment for genetic disease. The Lenetix scientific team has nearly 30 years of experience in developing new and innovative tests used by healthcare providers and researchers worldwide. For more information, visit www.lenetix.com.
|SOURCE Lenetix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved